
    
      Castration-resistant prostate cancer patients eligible for 2nd line hormonal treatment will
      undergo treatment with Enzalutamide (XTANDI). Subjects will receive 1dd 160 mg Enzalutamide
      orally continuously until progressive disease occurs.

      All subjects will undergo 18F-FDG PET/CT scans at baseline, 2 weeks, 2 and 6, 9 and 12 months
      after starting androgen receptor-directed treatment. All subjects will undergo Whole Body MRI
      at baseline, 6, 9 and 12 months. Bone scans will be performed at baseline, 3 months, 6 and 12
      months. PSA will be measured at baseline and every 4 weeks thereafter until at 12 months. CTC
      counts and characteristics will be measured at baseline and during Enzalutamide treatment.
    
  